MedPath

Orion Corporation, Orion Pharma

🇫🇮Finland
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

159

Active:60
Completed:90

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:86
Phase 2:14
+3 more phases

Drug Approvals

3

SFDA:3

Drug Approvals

NUBEQA

Approval Date
Jul 18, 2025
SFDA

BUFOMIX 160/4.5MCG EASYHALER

Approval Date
Jul 18, 2025
SFDA

BUFOMIX 320/9MCG EASYHALER

Approval Date
Jul 18, 2025
SFDA

Clinical Trials

Distribution across different clinical trial phases (126 trials with phase data)• Click on a phase to view related trials

Phase 1
86 (68.3%)
Phase 2
14 (11.1%)
Phase 4
9 (7.1%)
Not Applicable
8 (6.3%)
Phase 3
8 (6.3%)
Early Phase 1
1 (0.8%)

Efficacy and Tolerability of Tasipimidine in Sleepless Patients

Phase 2
Active, not recruiting
Conditions
Insomnia
Interventions
Drug: Tasipimidine placebo
First Posted Date
2025-05-04
Last Posted Date
2025-08-17
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
153
Registration Number
NCT06956495
Locations
🇫🇮

Terveystalo Helsinki Uniklinikka, Helsinki, Finland

Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours

Phase 1
Recruiting
Conditions
Solid Tumours
Interventions
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
315
Registration Number
NCT06725758
Locations
🇬🇧

Royal Marsden Hospital, London, UK, London, United Kingdom

Efficacy and Safety of Remo-Wax® Oil (RWO) in Subjects With Isolated Itching of the External Ear Canal

Not Applicable
Completed
Conditions
Itching
First Posted Date
2023-04-13
Last Posted Date
2023-10-06
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
36
Registration Number
NCT05811039
Locations
🇱🇹

Vilnius University Hospital, Vilnius, Lithuania

Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Indacaterol/glycopyrronium
First Posted Date
2022-03-18
Last Posted Date
2022-07-13
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
24
Registration Number
NCT05288075
Locations
🇫🇮

CRST Helsinki Oy, Helsinki, Finland

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2022-02-18
Last Posted Date
2022-08-18
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
88
Registration Number
NCT05246046
Locations
🇫🇮

Clinical Pharmacology Unit, Orion Corporation, Espoo, Finland

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 20
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.